ERBB2 and breast cancer: In metastatic HR+ HER2-negative breast cancer, previous studies have identified several prognostic indicators, including higher HER2 immunohistochemistry scores, estrogen receptor (ER) expression levels, Ki67 index, poor differentiation, and the presence of an objective response [27,28,29,30,31,32].